Molecular epidemiology of co‐infection with hepatitis B virus and human immunodeficiency virus (HIV) among adult patients in Harare, Zimbabwe

Baudi, Ian; Iijima, Sayuki; Chin'ombe, Nyasha; Mtapuri-Zinyowera, Sekesai; Murakami, Shuko; Isogawa, Masanori; Hachiya, Atsuko; Iwatani, Yoshinori; Tanaka, Yasuhito

doi:10.1002/jmv.24641

Cited by 10 publications

(7 citation statements)

References 28 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV/HIV coinfected patients: (n = 28 studies), [ 8 – 10 , 12 – 14 , 20 , 43 – 48 , 50 – 56 , 58 – 62 , 64 , 67 , 70 ];…”

Section: Resultsmentioning

confidence: 99%

“…This suite of mutations was identified in 14 studies [ 12 , 13 , 20 , 44 , 50 – 55 , 58 – 60 , 62 ], at a pooled prevalence of 4% (57/1462). Another significant VEM, sG145K/R [ 16 ], was identified in six studies [ 12 , 42 , 47 , 57 , 60 , 62 ] and sM133L/T, associated with VEM, immunoglobulin and diagnostic escape mutation [ 12 , 48 ], was identified in seven studies [ 12 , 41 , 47 , 48 , 57 , 62 , 70 ] ( Fig 2 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action

et al. 2018

View full text Add to dashboard Cite

International sustainable development goals for the elimination of viral hepatitis as a public health problem by 2030 highlight the pressing need to optimize strategies for prevention, diagnosis and treatment. Selected or transmitted resistance associated mutations (RAMs) and vaccine escape mutations (VEMs) in hepatitis B virus (HBV) may reduce the success of existing treatment and prevention strategies. These issues are particularly pertinent for many settings in Africa where there is high HBV prevalence and co-endemic HIV infection, but lack of robust epidemiological data and limited education, diagnostics and clinical care. The prevalence, distribution and impact of RAMs and VEMs in these populations are neglected in the current literature. We therefore set out to assimilate data for sub-Saharan Africa through a systematic literature review and analysis of published sequence data, and present these in an on-line database (https://livedataoxford.shinyapps.io/1510659619-3Xkoe2NKkKJ7Drg/). The majority of the data were from HIV/HBV coinfected cohorts. The commonest RAM was rtM204I/V, either alone or in combination with associated mutations, and identified in both reportedly treatment-naïve and treatment-experienced adults. We also identified the suite of mutations rtM204V/I + rtL180M + rtV173L, that has been associated with vaccine escape, in over 1/3 of cohorts. Although tenofovir has a high genetic barrier to resistance, it is of concern that emerging data suggest polymorphisms that may be associated with resistance, although the precise clinical impact of these is unknown. Overall, there is an urgent need for improved diagnostic screening, enhanced laboratory assessment of HBV before and during therapy, and sustained roll out of tenofovir in preference to lamivudine alone. Further data are needed in order to inform population and individual approaches to HBV diagnosis, monitoring and therapy in these highly vulnerable settings.

show abstract

“…HBV/HIV coinfected patients: (n = 28 studies), [ 8 – 10 , 12 – 14 , 20 , 43 – 48 , 50 – 56 , 58 – 62 , 64 , 67 , 70 ];…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Within the continent, data on the prevalence of pc mutations in both HBV mono‐infected and HIV‐HBV co‐infected patients are certainly available . However, their implications with respect to virological and serological response during anti‐HBV NA therapy remain to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

“…11 The pcG1896A mutation would then appear to impose serious consequences on the therapeutic course of NA-treated patients.Within the continent, data on the prevalence of pc mutations in both HBV mono-infected and HIV-HBV co-infected patients are certainly available. [12][13][14][15][16] However, their implications with respect to virological and serological response during anti-HBV NA therapy remain to be elucidated. In the study herein, we used unique data from a cohort of antiretroviral treatment (ART)-naïve HIV-HBV co-infected patients from Côte d'Ivoire initiating treatment with an anti-HBV containing regimen.…”

mentioning

confidence: 99%

Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co‐infected patients from Western Africa

Boyd

Moh

Maylin

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The nucleotide substitution G1896A on the precore (pc) region has been implicated in virological and serological responses during treatment in hepatitis B virus (HBV)-infected patients. Whether this mutation affects the therapeutic course of HIV-HBV co-infected patients, especially from Western Africa, is unknown. In this prospective cohort study, 86 antiretroviral (ARV)-naïve HIV-HBV co-infected patients from Côte d'Ivoire, initiating ARV-treatment containing lamivudine (n = 53) or tenofovir (n = 33), had available baseline pc sequences. Association of the pcG1896A mutation with time to undetectable HBV-DNA, hepatitis B "e" antigen (HBeAg) seroclearance (in HBeAg-positive patients), and hepatitis B surface antigen (HBsAg) seroclearance was evaluated using Cox proportional hazards regression. At ARV-initiation, median HBV-DNA was 6.04 log copies/mL (IQR = 3.70-7.93) with 97.7% harbouring HBV genotype E. Baseline pcG1896A mutation was identified in 51 (59.3%) patients, who were more commonly HBeAg-negative (P < .001) and had basal core promotor A1762T/G1764A mutations (P < .001). Patients were followed for a median 36 months (IQR = 24-36). Cumulative proportion of undetectable HBV-DNA was significantly higher in patients with baseline mutation (pcG1896A = 86.6% vs no pcG1896A = 66.9%, P = .04), but not after adjusting for baseline HBV-DNA levels and anti-HBV agent (P = .2). No difference in cumulative proportion of HBeAg seroclearance was observed between mutation groups (pcG1896A = 57.1% vs no pcG1896A = 54.3%, P = .7). Significantly higher cumulative proportion of HBsAg seroclearance was observed in patients without this mutation (pcG1896A = 0% vs no pcG1896A = 36.9%, P < .001), even after adjusting for baseline HBsAg quantification and anti-HBV agent (P < .001). In conclusion, lacking the pcG1896A mutation before ARV initiation appeared to increase HBsAg seroclearance rates during treatment. The therapeutic implications of this mutation need further exploration in this setting.

show abstract

“…Viral hepatitis B is caused by infection with hepatitis B virus (HBV) and is a worldwide epidemic disease. It is estimated that greater than two billion people (1/3 of the population) have been infected with hepatitis B . HBV infection can cause organ damage outside the liver, including sensory motor defects (5%), glomerulonephritis (3%), Sjogren's syndrome (3%), arthritis (3%), and myalgia (3%) .…”

Section: Introductionmentioning

confidence: 99%

Analysis of clinical features and pathology of serum HBsAg positive glomerulonephritis

Peng

Xie

Liu

et al. 2017

Journal of Medical Virology

View full text Add to dashboard Cite

To analyze the relationship between the factors related to the occurrence of HBV-GN and serum HBsAg-positive glomerulonephritis. A total of 56 patients were enrolled in the present study. All enrolled cases were divided into two groups according to whether HBsAg and/or HBcAg was present in renal kidney tissue: patients with Hepatitis B virus-associated nephritis (HBV-GN group, 30 cases) and patients with hepatitis B virus-combined nephritis (HBV-CG group, 26 cases). We sought to analyze the differences in clinical features and pathological characteristics in both groups. The rate of HBeAg positivity in the HBV-GN group was considerably increased in the HBV-CG group (P < 0.05), and the number of patients with HBsAg+HBeAg+HBcAb+ in the HBV-GN group was considerably increased in the HBV-CG group (21 cases vs 10 cases) (P < 0.05). Moreover, the number of MCD patients diagnosed by renal biopsy in the HBV-GN group was reduced compared with the HBV-CG group (1 case vs 7 cases) (P < 0.05). HBV infection and high-virus proliferation status were closely related with HBV-GN.

show abstract

Molecular epidemiology of co‐infection with hepatitis B virus and human immunodeficiency virus (HIV) among adult patients in Harare, Zimbabwe

Cited by 10 publications

References 28 publications

A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action

A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action

Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co‐infected patients from Western Africa

Analysis of clinical features and pathology of serum HBsAg positive glomerulonephritis

Contact Info

Product

Resources

About